It has been argued that in the pancreatic cancer, Fsp1/S100A4 but not αSMA is the most consistent and predominant mesenchymal marker associated with the EMT program (Rhim et al, 2012; Fischer et al, 2015; Aiello et al, 2016). This evidence concerns the gene S100A4 and pancreatic neoplasm.